Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | COURTINARD, Coralie | |
| dc.contributor.author | GOURGOU, Sophie | |
| dc.contributor.author | JACOT, William | |
| dc.contributor.author | CARTON, Matthieu | |
| dc.contributor.author | GUERIN, Olivier | |
| dc.contributor.author | VACHER, Laure | |
| dc.contributor.author | BERTAUT, Aurelie | |
| dc.contributor.author | LE DELEY, Marie-Cecile | |
| dc.contributor.author | PEROL, David | |
| dc.contributor.author | MARINO, Patricia | |
| dc.contributor.author | LEVY, Christelle | |
| dc.contributor.author | UWER, Lionel | |
| dc.contributor.author | PERROCHEAU, Genevieve | |
| dc.contributor.author | SCHIAPPA, Renaud | |
| dc.contributor.author | BACHELOT, Florence | |
| dc.contributor.author | PARENT, Damien | |
| dc.contributor.author | BRETON, Mathias | |
| dc.contributor.author | PETIT, Thierry | |
| dc.contributor.author | FILLERON, Thomas | |
| dc.contributor.author | LOEB, Agnes | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MATHOULIN-PELISSIER, Simone | |
| dc.contributor.author | ROBAIN, Mathieu | |
| dc.contributor.author | DELALOGE, Suzette | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BELLERA, Carine | |
| dc.date.accessioned | 2023-04-17T12:49:12Z | |
| dc.date.available | 2023-04-17T12:49:12Z | |
| dc.date.issued | 2023-03-08 | |
| dc.identifier.issn | 1741-7015 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/173020 | |
| dc.description.abstractEn | BACKGROUND: Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the individual-level association between real-world PFS (rwPFS) and OS according to first-line treatment in female patients with mBC managed in real-world setting for each BC subtype (defined by status for both hormone-receptor [HR] expression and HER2 protein expression/gene amplification). METHODS: We extracted data from the ESME mBC database (NCT03275311) which gathers deidentified data from consecutive patients managed in 18 French Comprehensive Cancer Centers. Adult women diagnosed with mBC between 2008 and 2017 were included. Endpoints (PFS, OS) were described using the Kaplan-Meier method. Individual-level associations between rwPFS and OS were estimated using the Spearman's correlation coefficient. Analyses were conducted by tumor subtype. RESULTS: 20,033 women were eligible. Median age was 60.0 years. Median follow-up duration was 62.3 months. Median rwPFS ranged from 6.0 months (95% CI 5.8-6.2) for HR-/HER2 - subtype to 13.3 months (36% CI 12.7-14.3) for HR + /HER2 + subtype. Correlation coefficients were highly variable across subtypes and first-line (L1) treatments. Among patients with HR - /HER2 - mBC, correlation coefficients ranged from 0.73 to 0.81, suggesting a strong rwPFS/OS association. For HR + /HER2 + mBC patients, the individual-level associations were weak to strong with coefficients ranging from 0.33 to 0.43 for monotherapy and from 0.67 to 0.78 for combined therapies. CONCLUSIONS: Our study provides comprehensive information on individual-level association between rwPFS and OS for L1 treatments in mBC women managed in real-life practice. Our results could be used as a basis for future research dedicated to surrogate endpoint candidates. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Real-word data | |
| dc.subject.en | Breast cancer | |
| dc.subject.en | Overall survival | |
| dc.subject.en | Progression-free survival | |
| dc.subject.en | Association | |
| dc.subject.en | Surrogacy | |
| dc.title.en | Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database | |
| dc.title.alternative | BMC Med | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1186/s12916-023-02754-5 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 36882736 | en_US |
| bordeaux.journal | BMC Medicine | en_US |
| bordeaux.volume | 21 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04071677 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-04-17T12:49:16Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Medicine&rft.date=2023-03-08&rft.volume=21&rft.issue=1&rft.eissn=1741-7015&rft.issn=1741-7015&rft.au=COURTINARD,%20Coralie&GOURGOU,%20Sophie&JACOT,%20William&CARTON,%20Matthieu&GUERIN,%20Olivier&rft.genre=article |
